- Home
- VLYPO vs EXEL Comparison
VLYPO vs EXEL Comparison
Compare VLYPO & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
VLYPO
Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B
Current Price
Company Overview
Basic Information| Metric | VLYPO | EXEL |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | United States |
| Employees | 3732 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 11.1B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | VLYPO | EXEL |
|---|---|---|
| Price | $25.59 | $40.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 24 |
| Target Price | N/A | ★ $45.18 |
| AVG Volume (30 Days) | N/A | ★ 2.6M |
| Earning Date | N/A | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.55 |
| EPS | N/A | ★ 2.38 |
| Revenue | N/A | ★ $2,288,218,000.00 |
| Revenue This Year | N/A | $9.84 |
| Revenue Next Year | N/A | $11.92 |
| P/E Ratio | ★ N/A | $17.20 |
| Revenue Growth | N/A | ★ 9.93 |
| 52 Week Low | N/A | $31.90 |
| 52 Week High | N/A | $49.62 |
Technical Indicators
Market Signals| Indicator | VLYPO | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 53.55 | 43.05 |
| Support Level | $25.12 | $43.00 |
| Resistance Level | $25.59 | $44.79 |
| Average True Range (ATR) | 0.15 | 1.15 |
| MACD | 0.01 | -0.45 |
| Stochastic Oscillator | 53.00 | 3.65 |
Price Performance
Historical ComparisonAbout VLYPO Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.